Omega Laboratories Reports
Completion of Method Validation with Cannabix Technologies Inc. for
Marijuana Breath Detection
Vancouver, British
Columbia, Canada -- March 18, 2025 -- InvestorsHub NewsWire --
Cannabix Technologies Inc. (CSE:
BLO) (OTC
PINK: BLOZF) (Frankfurt: 8CT) (the "Company or Cannabix")
reports the following news release was issued by Omega
Laboratories, Inc. today.
MOGADORE,
Ohio, March 18, 2025 -- Omega Laboratories, a leading
drug testing laboratory renowned for its comprehensive services,
proudly announces the development and validation of a marijuana
breath test. This validation includes a test method for the
simultaneous quantification of Delta-9-tetrahydrocannabinol (THC),
Delta-8-THC, cannabidiol (CBD), and cannabinol (CBN) in breath
aerosols collected using Cannabix Technologies' Breath Collection
Unit (BCU). This establishes Omega and Cannabix as the premier
technology for collecting and testing breath for recent marijuana
usage. This method validation marks a significant milestone in the
pursuit of innovative solutions for drug testing and safety
assurance.
Cannabix
Technologies Inc. and Omega have collaborated to optimize the
design of the Cannabix BCU and compact Breath Cartridge
technology. The BCU includes a start-up unit air flow
self-check, the ability to collect an ambient air sample to rule
out external contamination from the immediate surrounding area, a
split sample configured Breath Cartridge to simultaneously collect
an A and B sample, and a collection system that will stop drawing
in air should the donor stop breathing into the device. This
prevents the device from pulling in ambient air from the
surrounding area and a donor from trying to cheat the collection.
The Cannabix BCU is at the forefront of advanced breath collection
tools to collect breath accurately and non-invasively.
Omega Laboratories
is currently in the process of incorporating breath testing into
its suite of services. With credible and extensive research backing
Cannabix's technology, including validation studies demonstrating
its efficacy, Omega Laboratories is confident in the reliability
and accuracy of the THC breath test system. In partnership with
Cannabix, Omega has completed a full validation study that will be
published to further demonstrate the effectiveness of the breath
testing system in real-world testing scenarios. This will
ensure unparalleled accuracy and reliability for clients.
"At Cannabix
Technologies, we are thrilled with the method validation results
from Omega Laboratories, a company that upholds a tradition of
excellence in drug testing, backed by their extensive
accreditations and certifications,", stated, Rav Mlait, CEO of
Cannabix Technologies Inc. "This partnership success further
solidifies our commitment to providing trusted and highly
accredited solutions, offering unparalleled expertise and
reliability to future clients."
The integration of
Cannabix's THC BCU technology with Omega Laboratories' testing
protocols will enable rapid and precise detection of THC levels
in breath samples. This innovative approach not only streamlines
the testing process but also ensures reliable results for clients
across various industries, including law enforcement, workplace
safety, and healthcare.
Furthermore, as
part of this collaboration, all breath samples analyzed by Omega
Laboratories undergo a testing process using mass spectrometry
(mass spec), a gold standard in analytical chemistry to confirm
which analytes are present. This meticulous approach reinforces
Omega's commitment to maintaining the highest forensic standards of
quality and integrity.
With the rise in
cannabis legalization, employers face new challenges in detecting
recent use of marijuana. Traditional cannabis testing methods, such
as oral fluid, urine, and hair tests, can detect cannabis use for
extended periods, ranging from days to months. The premier solution
for recent use detection will be utilizing the Cannabix BCU to
collect breath then sending the sample to Omega for analysis. Omega
will then detect if there was recent THC usage (minutes to several
hours).
"Our partnership
with Cannabix Technologies underscores our commitment to staying at
the forefront of advancements in drug testing technology," said
Bill Corl, CEO of Omega Laboratories. "By incorporating their
groundbreaking THC breath collection technology, we are poised to
enhance the accuracy, efficiency, and accessibility of cannabis
testing."
About Omega Laboratories, Inc.
Omega
Laboratories, headquartered in Mogadore, Ohio with an additional
state-of-the-art facility in Ontario, Canada provides
laboratory-based advanced testing solutions to over 6,000 clients
worldwide. Omega Laboratories has over 24 years of experience in
pioneering innovative drug testing methodologies, specializing in
the detection of drugs of abuse utilizing Hair, Oral Fluid, Urine
and Breath specimens. Omega continues to innovate with the launch
of their Technical Solutions portfolio that incorporates a
paperless Custody & Control Form system (oCCF) in fourteen
languages, licensure of a Laboratory Information Management System
(LIMS) designed specifically for Toxicology and powers new
laboratories in countries that have demand for local service
providers.
Omega Laboratories, Inc Contact: For additional
information on these solutions, please contact Omega at
1-800-665-5569 or sales@omegalabs.net .
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol
breath testing technologies for a range of workplaces, law
enforcement and other settings. Breath testing for delta-9 THC (the
primary psychoactive ingredient in
cannabis) would allow employers and law enforcement
to identify recent marijuana use. Cannabix is the developer of
the Breath Logix autonomous
alcohol screening device for organizations who strive to improve
alcohol safety and monitoring.
We seek Safe
Harbor.
On behalf of the Board of Directors
"Rav Mlait"
CEO
Cannabix
Technologies Inc.
For further
information, contact the Company at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept
responsibility for the adequacy or accuracy of this
release.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain
"forward-looking statements" within the meaning of such statements
under applicable securities law. Forward-looking statements are
frequently characterized by words such as "anticipates," "plan,"
"continue," "expect," "project," "intend," "believe," "anticipate,"
"estimate," "may," "will," "potential," "proposed," "positioned"
and other similar words, or statements that certain events or
conditions "may" or "will" occur. Forward-looking statements in
this news release include, but are not limited to, statements
relating to: certification of devices, acceptance of devices by
international regulators, the achievement of any or all of the
goals and aims of the strategic
partnership and development agreement with Omega Laboratories; the
completion of pre-validation or validation testing described in
this news release; final development of a commercial or prototype
product(s); the successful trial or pilot of company technologies;
the commercialization of the Company's products; the negotiation
and potential entry into additional agreements with distributors;
and the completion of future financings. There are numerous risks
and uncertainties that could cause actual results and the Company's
plans and objectives to differ materially from those expressed in
the forward-looking information. Important factors that could cause
actual results to differ materially from those expressed in the
forward-looking information include (but are note limited to):
adverse market conditions; risks regarding protection of
proprietary technology; the ability of the Company to complete
future financings; the ability of the Company to develop and market
its future product; risks regarding government regulation, managing
and maintaining growth, the effect of adverse publicity,
litigation, competition; that Omega may not complete all or any of
the milestones as contemplated strategic partnership and
development agreement with Omega Laboratories; that the CSE may not
approve the issuance of the securities; that the Company's
development of breathalyzer technology will provide any benefit to
the Company; there is no assurance that any proposed new products
will be built, will be successful in beta testing or clinical
trials; there is no assurance that the Company will enter into any
partnerships to advance any of its corporate initiatives or
technologies; there is no assurance that any "patent pending" or
"provisional patents" technologies licensed by the Company or owned
by the Company will receive patent status by regulatory
authorities; the Company is not currently selling breathalyzers and
there is no assurance that the Company ever will; and other factors
beyond the control of the Company. Actual results and future events
could differ materially from those anticipated in such information.
These and all subsequent written and oral forward-looking
information are based on estimates and opinions of management on
the dates they are made and are expressly qualified in their
entirety by this notice. Except as required by law, the Company
does not intend to update these forward-looking
statements.
501-3292 Production Way, Burnaby, B.C., V5A 4R4
Phone: (604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com